A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained
- 7 August 2014
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 465 (4) , 487-494
Abstract
Some primary malignant or benign tumours of bone contain numerous multinucleated cells. These “giant cell-rich tumours of bone” have overlapping features and clinical and radiological data are needed to reach an accurate pathological diagnosis. We studied the potential contribution of p63 immunohistochemistry to the reliability of the histological diagnosis. We performed a multicentric retrospective study of 291 giant cell-rich tumours of bone which included 119 giant cell tumours of bone (GCTB), 76 aneurysmal bone cysts (ABC), 49 chondroblastomas (CB), 15 nonossifying fibromas (NOF), 10 giant cell reparative granulomas (RG) of jaws, 1 giant cell lesion of small bones, 2 hyperparathyroidism-related brown tumours (BT), 17 bone sarcomas with numerous osteoclasts and 2 malignant giant cell tumours of bone. p63 is expressed in ABC, CB, NOF, RG, BT and GCTB, but its expression in more than 50 % of mononuclear cells is strongly suggestive of a diagnosis of GCTB. In contrast, malignant GCTB were mostly negative. Our results show that p63 is expressed in a broad range of benign giant cell-rich tumours of bone, consistent with data in the recent literature, while infrequent in malignant tumours. With a cut-off 50 %, the presence of p63 positive cells is useful in supporting a diagnosis of giant cell-rich tumour of bone. However, a final diagnosis cannot be made without due consideration of all clinical/radiological and pathological data.Keywords
This publication has 24 references indexed in Scilit:
- p63 regulates cell proliferation and cell cycle progression-associated genes in stromal cells of giant cell tumor of the boneInternational Journal of Oncology, 2012
- p63 as a prognostic marker for giant cell tumor of boneUpsala Journal of Medical Sciences, 2012
- Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experienceDiagnostic Pathology, 2012
- Smooth muscle actin expression in primary bone tumoursVirchows Archiv, 2012
- Morphological and immunophenotypic features of primary and metastatic giant cell tumour of boneVirchows Archiv, 2009
- Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the boneLaboratory Investigation, 2008
- Giant cell tumor of bone express p63Laboratory Investigation, 2008
- Giant cell tumour of bone: morphological, biological and histogenetical aspectsInternational Orthopaedics, 2006
- Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genesOncogene, 2005
- USP6 and CDH11 Oncogenes Identify the Neoplastic Cell in Primary Aneurysmal Bone Cysts and Are Absent in So-Called Secondary Aneurysmal Bone CystsThe American Journal of Pathology, 2004